This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Dong Wha Pharmaceutical Industrial Co., Ltd.. Active years: 1996-2003.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Anyang, KR (1996)
- Kyunggi-do, KR (2001 - 2003)
Company Filing History:
Years Active: 1996-2003
Title: Chi-Woo Lee: Innovator in Antibacterial Compounds
Introduction
Chi-Woo Lee is a notable inventor based in Gyeonggi, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibacterial agents. With a total of 3 patents, his work has the potential to impact medical treatments significantly.
Latest Patents
One of Chi-Woo Lee's latest patents focuses on quinolone carboxylic acid derivatives. This invention relates to novel quinolone carboxylic acid derivatives that exhibit superior and broader antibacterial activities compared to existing quinolone-series antibiotics. Specifically, it pertains to compounds represented by a specific formula, which includes a derivative of 7-[8-(alkoxyimino)-2,6-diazaspiro[3.4]oct-6-yl] as a substituent, along with pharmaceutically acceptable salts and isomers thereof.
Career Highlights
Throughout his career, Chi-Woo Lee has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Dong Wha Pharmaceutical Industrial Co., Ltd. and Bioway, Inc. His work in these organizations has allowed him to develop innovative solutions in the field of medicine.
Collaborations
Chi-Woo Lee has collaborated with several professionals in his field, including Yoon-Seok Oh and Nam-Doo Kim. These collaborations have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Chi-Woo Lee is a distinguished inventor whose work in antibacterial compounds showcases his innovative spirit and dedication to improving healthcare. His contributions are expected to have a lasting impact on the pharmaceutical industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile